Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is 44.89% higher on its value in year-to-date trading and has touched a low of $141.98 and a high of $285.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALNY stock was last observed hovering at around $279.17 in the last trading session, with the day’s loss setting it -1.84%.
Currently trading at $277.33, the stock is 6.36% and 16.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.53 million and changing -0.66% at the moment leaves the stock 52.70% off its SMA200. ALNY registered 46.95% gain for a year compared to 6-month gain of 70.34%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 17.27% loss in the last 1 month and extending the period to 3 months gives it a 83.78%, and is 5.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.17% over the week and 3.46% over the month.
Alnylam Pharmaceuticals Inc (ALNY) has around 2100 employees, a market worth around $35.60B and $2.34B in sales. Profit margin for the company is -3.11%. Distance from 52-week low is 95.34% and -2.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-2.80%).
The EPS is expected to grow by 29.27% this year
817.0 institutions hold shares in Alnylam Pharmaceuticals Inc (ALNY), with institutional investors hold 95.93% of the company’s shares. The shares outstanding are 128.38M, and float is at 127.22M with Short Float at 3.40%. Institutions hold 95.53% of the Float.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 14.97 million shares valued at $3.64 billion. The investor’s holdings represent 11.869 of the ALNY Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.51 million shares valued at $3.04 billion to account for 9.9159 of the shares outstanding. The other top investors are FMR LLC which holds 12.16 million shares representing 9.6434 and valued at over $2.96 billion, while BLACKROCK INC. holds 7.5692 of the shares totaling 9.55 million with a market value of $2.32 billion.
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
The most recent transaction is an insider sale by Greenstreet Yvonne, the company’s Chief Executive Officer. SEC filings show that Greenstreet Yvonne sold 15,000 shares of the company’s common stock on Aug 20 ’24 at a price of $280.00 per share for a total of $4.2 million. Following the sale, the insider now owns 73441.0 shares.
Still, SEC filings show that on Aug 12 ’24, Fitzgerald Kevin Joseph (CSO & EVP, Head of Research) disposed off 22,025 shares at an average price of $270.99 for $5.97 million. The insider now directly holds 12,881 shares of Alnylam Pharmaceuticals Inc (ALNY).
